Friday 6 November 2026 Export KOD’s income statement to Excel — free account

Kodiak Sciences Inc.

KOD Healthcare Biotechnology

EPS: −1.94%
Free cash flow: −33.9%

Quarter to June 2026, against a year earlier

Insider buying

98.85 7.83 +8.60%

Follow KOD

Alert me

Market cap: $5.7B
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Valuation Filings

Kodiak Sciences Inc. 10-Q filed Aug 13, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed Aug 13, 2026 · accepted 4:17 PM ET · Document on sec.gov · Filing index

Red flags

Share dilution Aug 13, 2026
Shares outstanding rose 19.0% in a year, to 62.8 million

10-Q filed Aug 13, 2026 · The filing · sec.gov
Short cash runway Aug 13, 2026
Kodiak Sciences Inc.’s cash and short-term investments cover about 3.2 quarters of its operating cash burn

10-Q filed Aug 13, 2026 · The filing · sec.gov

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part II, Item 1A, Risk Factors, against the 10-Q filed May 7, 2026: no comparison — low extraction confidence